Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo -: A study using the novel PPARα/γ agonist tesaglitazar

被引:60
作者
Hegarty, BD
Furler, SM
Oakes, ND
Kraegen, EW
Cooney, GJ
机构
[1] St Vincents Hosp, Garvan Inst Med Res, Diabet & Obes Res Program, Sydney, NSW 2010, Australia
[2] AstraZeneca R&D, S-43183 Molndal, Sweden
关键词
D O I
10.1210/en.2004-0260
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Agonists of peroxisome proliferator-activated receptors (PPARs) have emerged as important pharmacological agents for improving insulin action. A major mechanism of action of PPAR agonists is thought to involve the alteration of the tissue distribution of nonesterified fatty acid ( NEFA) uptake and utilization. To test this hypothesis directly, we examined the effect of the novel PPARalpha/gamma agonist tesaglitazar on whole-body insulin sensitivity and NEFA clearance into epididymal white adipose tissue (WAT), red gastrocnemius muscle, and liver in rats with dietary-induced insulin resistance. Wistar rats were fed a high-fat diet (59% of calories as fat) for 3 wk with or without treatment with tesaglitazar (1 mumol.kg(-1).d(-1), 7 d). NEFA clearance was measured using the partially metabolizable NEFA tracer, H-3-R-bromopalmitate, administered under conditions of basal or elevated NEFA availability. Tesaglitazar improved the insulin sensitivity of high-fat-fed rats, indicated by an increase in the glucose infusion rate during hyperinsulinemic-euglycemic clamp (P < 0.01). This improvement in insulin action was associated with decreased diglyceride (P < 0.05) and long chain acyl coenzyme A (P < 0.05) in skeletal muscle. NEFA clearance into WAT of high-fat-fed rats was increased 52% by tesaglitazar under basal conditions (P < 0.001). In addition the PPARalpha/gamma agonist moderately increased hepatic and muscle NEFA utilization and reduced hepatic triglyceride accumulation (P < 0.05). This study shows that tesaglitazar is an effective insulin-sensitizing agent in a mild dietary model of insulin resistance. Furthermore, we provide the first direct in vivo evidence that an agonist of both PPAR alpha and PPAR gamma increases the ability of WAT, liver, and skeletal muscle to use fatty acids in association with its beneficial effects on insulin action in this model.
引用
收藏
页码:3158 / 3164
页数:7
相关论文
共 45 条
[1]   Molecular or pharmacologic perturbation of the link between glucose and lipid metabolism is without effect on glucose-stimulated insulin secretion - A re-evaluation of the long-chain acyl-CoA hypothesis [J].
Antinozzi, PA ;
Segall, L ;
Prentki, M ;
McGarry, JD ;
Newgard, CB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (26) :16146-16154
[2]   INSULIN ACTION AND GLUCOSE-METABOLISM ARE IMPROVED BY GEMFIBROZIL TREATMENT IN HYPERTRIGLYCERIDEMIC PATIENTS [J].
AVOGARO, A ;
BELTRAMELLO, P ;
BONANOME, A ;
BIFFANTI, S ;
MARIN, R ;
ZAMBON, S ;
CONFORTIN, L ;
MANZATO, E ;
CREPALDI, G ;
TIENGO, A .
ATHEROSCLEROSIS, 1995, 113 (01) :117-124
[3]   Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients [J].
Avogaro, A ;
Miola, M ;
Favaro, A ;
Gottardo, L ;
Pacini, G ;
Manzato, E ;
Zambon, S ;
Sacerdoti, D ;
de Kreutzenberg, S ;
Piliego, T ;
Tiengo, A ;
Del Prato, S .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2001, 31 (07) :603-609
[4]   New pharmacologic agents for diabetes. [J].
Bailey C.J. .
Current Diabetes Reports, 2001, 1 (2) :119-126
[5]   Peroxisome proliferator-activated receptor (PPAR) γ and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle [J].
Cha, BS ;
Ciaraldi, TP ;
Carter, L ;
Nikoulina, SE ;
Mudaliar, S ;
Mukherjee, R ;
Paterniti, JR ;
Henry, RR .
DIABETOLOGIA, 2001, 44 (04) :444-452
[6]   PENTOBARBITAL REDUCES BASAL LIVER GLUCOSE OUTPUT AND ITS INSULIN SUPPRESSION IN RATS [J].
CLARK, PW ;
JENKINS, AB ;
KRAEGEN, EW .
AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 258 (04) :E701-E707
[7]  
Cooney GJ, 2002, ANN NY ACAD SCI, V967, P196
[8]   Structure of the PPARα and -γ ligand binding domain in complex with AZ 242;: Ligand selectivity and agonist activation in the PPAR family [J].
Cronet, P ;
Petersen, JFW ;
Folmer, R ;
Blomberg, N ;
Sjöblom, K ;
Karlsson, U ;
Lindstedt, EL ;
Bamberg, K .
STRUCTURE, 2001, 9 (08) :699-706
[9]   Peroxisome proliferator-activated receptors: Nuclear control of metabolism [J].
Desvergne, B ;
Wahli, W .
ENDOCRINE REVIEWS, 1999, 20 (05) :649-688
[10]   Peroxisome proliferator-activated receptors: insight into multiple cellular functions [J].
Escher, P ;
Wahli, W .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2000, 448 (02) :121-138